Top Suppliers:I want be here
Related CAS#:
461432-26-8 461432-25-7
1204219-80-6 1408245-02-2
960404-86-8 2100872-88-4
2452300-79-5 1528636-07-8
2001088-28-2 1351438-75-9
1158522-08-7 940364-43-2
1369895-47-5 1330784-34-3
134104-43-1 131615-57-1
6906-52-1 912903-01-6
85952-76-7 930439-75-1

461432-26-8

461432-26-8 structure
461432-26-8 structure
  • Name: dapagliflozin
  • Chemical Name: dapagliflozin
  • CAS Number: 461432-26-8
  • Molecular Formula: C21H25ClO6
  • Molecular Weight: 408.873
  • Catalog: Pharmaceutical intermediate API intermediate
  • Create Date: 2018-02-07 08:00:00
  • Modify Date: 2024-01-02 16:27:47
  • Dapagliflozin (BMS-512148) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Name dapagliflozin
Synonyms D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-,(1S)
Dapagliflozin
Forxiga
D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-
(1S)-1,5-Anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol
Forxiga (TN)
[14C]-Dapagliflozin
(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
dapaglifozin
(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethy)tetrahydro-2H-pyran-3,4,5-triol
Farxiga
S1548_Selleck
(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
BMS 512148
Description Dapagliflozin (BMS-512148) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Related Catalog
Target

SGLT2[1]

In Vitro Dapagliflozin pretreatment of hypoxic HK2 cells significantly improves the cell viability in a dose-dependent manner. Dapagliflozin decreases Bax expression, the Bax/Bcl2 ratio, and PARP expression in hypoxic HK2 cells[2].
In Vivo At 11 mM glucose, dapagliflozin raises glucagon release from 18% to 32% of control, while the effect of dapagliflozin addition is minor at 1 mM glucose. At the intermediate glucose concentration of 6 mM, glucagon secretion is estimated to be 24% and 30% of control in the absence or presence of dapagliflozin, respectively[1]. Dapagliflozin pretreatment significantly reduces the number of TUNEL-positive cells in IR-injured kidneys. Dapagliflozin pretreatment significantly elevates the HIF1 expression in IR-injured renal tubular cells from mice[2]. Dapagliflozin (10 mg/kg, o.p.) causes a marked increase in urinary glucose in SGLT2i-mice. Dapagliflozin acutely suppresses BAT thermogenesis by reducing sympathetic nerve activity. Dapagliflozin enhances hepatic gluconeogenesis and glycogenolysis[3].
Cell Assay To perform the cell survival assay, cells are collected after 24 h incubation with vehicle or dapagliflozin pretreatment in 30-min ischemia and surviving cells are counted with Trypan blue staining. The percentage survival is determined by quantization of the relative viable number of treated cells divided by the viable number of untreated cells.
Animal Admin 10-week-old male C57BL/6 mice weighing 30-33 g each are divided into five groups: vehicle (Vh)-treated sham (n=5), dapagliflozin-treated sham (n=5), Vh-treated IR (n=7), dapagliflozin-treated IR (n=7), and albendazole and dapagliflozin treated IR (n=7). Dapagliflozin is administrated via oral gavage at a dose of 10 mg/kg/day for 2 days, starting 24 h before surgery. Albendazole is injected subcutaneously 1 h before IR surgery.
References

[1]. Pedersen MG, et al. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci Rep. 2016 Aug 18;6:31214.

[2]. Yoon-Kyung Chang, et al. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. PLoS One. 2016; 11(7): e0158810.

[3]. Chiba Y, et al. Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLoS One. 2016 Mar 10;11(3):e0150756.

[4]. Akahane K, et al. Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats. Drug Res (Stuttg). 2015 Aug;65(8):416-21.

[5]. Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018 Jun 13;15(9):937-943.
Density 1.3±0.1 g/cm3
Boiling Point 609.0±55.0 °C at 760 mmHg
Molecular Formula C21H25ClO6
Molecular Weight 408.873
Flash Point 322.1±31.5 °C
Exact Mass 408.133972
PSA 99.38000
LogP 4.42
Vapour Pressure 0.0±1.8 mmHg at 25°C
Index of Refraction 1.614
461432-24-6 structure

461432-24-6

~43%

461432-26-8 structure

461432-26-8

Literature: WO2010/48358 A2, ; Page/Page column 32-33 ; WO 2010/048358 A2
714269-57-5 structure

714269-57-5

~%

461432-26-8 structure

461432-26-8

Literature: US2008/4336 A1, ; Page/Page column 21-22 ;
90-80-2 structure

90-80-2

~%

461432-26-8 structure

461432-26-8

Literature: WO2013/152476 A1, ;
19094-56-5 structure

19094-56-5

~%

461432-26-8 structure

461432-26-8

Literature: WO2013/152476 A1, ;
32469-28-6 structure

32469-28-6

~%

461432-26-8 structure

461432-26-8

Literature: WO2013/152476 A1, ;
21739-92-4 structure

21739-92-4

~%

461432-26-8 structure

461432-26-8

Literature: Journal of Medicinal Chemistry, , vol. 57, # 4 p. 1236 - 1251
864070-18-8 structure

864070-18-8

~%

461432-26-8 structure

461432-26-8

Literature: Journal of Medicinal Chemistry, , vol. 57, # 4 p. 1236 - 1251
498-07-7 structure

498-07-7

~%

461432-26-8 structure

461432-26-8

Literature: US2014/128595 A1, ;
21900-52-7 structure

21900-52-7

~%

461432-26-8 structure

461432-26-8

Literature: Journal of Medicinal Chemistry, , vol. 57, # 4 p. 1236 - 1251

Chemsrc provides CAS#:461432-26-8 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 461432-26-8 | Chemsrc address: https://m.chemsrc.com/en/baike/951294.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved